Research programme: anti-cancer therapeutics - VECT-HORUS
Latest Information Update: 21 Jul 2021
At a glance
- Originator VECT-HORUS
- Class Antineoplastics; Drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 06 Jul 2021 VECT-HORUS has patent protection for peptide and small antibody based vectors (VECT-HORUS pipeline July 2021)
- 06 Jul 2021 VECT-HORUS has patents pending for vectorised neuroprotective agent and for new vectors (VECT-HORUS pipeline July 2021)
- 05 Jul 2021 Preclinical trials in Cancer in France (Parenteral) (VECT-HORUS pipeline, July 2021)